Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
SOURCE Research and Markets
DUBLIN, March 7, 2018 /PRNewswire/ --
The "Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
Hypertrophic scars currently exhibits a growing pipeline with nine drug candidates.
Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.
Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream's safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.
The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.
Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.
Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.
Key Topics Covered:
Chapter 1. Research Background
1.1 Research Objectives
1.3 Research Scope
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.2 Key Drivers
4.3 Key Barriers
4.4 Hypertrophic Scars Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company
Chapter 5. Hypertrophic Scars Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase II: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.2 Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.3 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.4 Discontinued Drugs
Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Hypertrophic Scars Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Hypertrophic Scars Therapeutics Pipeline
Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Hypertrophic Scars Therapeutics Pipeline
7.2 SWOT Analysis Hypertrophic Scars Therapeutics Pipeline
Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings
For more information about this report visit https://www.researchandmarkets.com/research/4f22sd/global?w=5
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
©2017 PR Newswire. All Rights Reserved.